Electromed, Inc. (ELMD) Earnings Call Transcripts
Electromed, Inc.'s Latest Earnings Call - Q3 FY2026
In the third quarter of fiscal 2026, Electromed, Inc. (ELMD) reported revenue of $18.6 million, reflecting an 18.4% year-over-year increase, and a diluted EPS of $0.35, up 67% from the prior year. The strong performance was driven by broad-based growth across segments, particularly a 43% increase in hospital revenue. Management maintained a positive outlook, indicating continued double-digit revenue growth potential, although they noted that recent growth rates may not represent a new normal.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $18.6 million (beat) |
| Operating Income | $3.8 million (beat) |
| Diluted EPS | $0.35 (beat) |
| Gross Profit Margin | 78.8% (beat) |
| Cash Position | $17 million (neutral) |
| Sales Representatives | 58 (neutral) |
Guidance from management
Management expressed confidence in maintaining double-digit revenue growth but acknowledged that recent growth rates may not be sustainable as a new normal. They are focused on capturing the bronchiectasis market opportunity moving forward.
What management said
Thank you, operator. And for everybody that's on the call. In summary, our fiscal third quarter demonstrate [ tremendous ] firing on all cylinders. We delivered strong financial results and executing against the largely untapped bronchiectasis opportunity with precision and purpose. Our team is focused, our strategy is working, and we have significant runway ahead of us. I want to thank our exceptional team for thei...
What analysts pressed on
Analysts expressed concerns about the ramp-up time for new sales representatives and the potential impact of turnover within the sales team. There were also questions regarding the effectiveness of recent educational initiatives in converting awareness into prescriptions.
Main topics on the call
- Revenue Growth Acceleration — Electromed achieved revenue of $18.6 million in Q3, marking an 18.4% increase year-over-year. CEO Jim Cunniff stated, "This performance reflects the strength of our commercial execution and the growing recognition of Sma...
- Record Operating Income — Operating income surged to $3.8 million, a 76% increase from the previous year, demonstrating effective cost management and revenue growth. Cunniff emphasized, "Even more impressive is our record bottom line performance....
- Bronchiectasis Market Opportunity — Management highlighted the significant opportunity in the bronchiectasis market, noting that approximately 800,000 diagnosed patients are not receiving therapy. Cunniff remarked, "This represents the primary strategic op...
- Sales Force Expansion — Electromed ended the quarter with 58 direct sales representatives and plans to increase this to 62. The company noted that the ramp-up period for new reps is typically 4 to 6 months, which is critical for revenue growth.
Read the full Electromed, Inc. transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Electromed, Inc.
Electromed, Inc. (ELMD) is a publicly listed company in the Health Care Equipment and Supplies industry, within the Health Care sector. It trades on NYSEAM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 27 calls on record spanning February 12, 2020 to May 12, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 27 Electromed, Inc. earnings call transcripts on record, spanning February 12, 2020 to May 12, 2026. Based on this history, Electromed, Inc. reports quarterly. The most recent call on file is dated May 12, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ELMD
- Exchange
- NYSEAM
- Country
- US
- Sector
- Health Care
- Calls on record
- 27
- First call
- February 12, 2020
- Most recent
- May 12, 2026
- Reporting cadence
- quarterly